{
    "doi": "https://doi.org/10.1182/blood.V130.Suppl_1.2046.2046",
    "article_title": "Haplo-Identical Stem Cell Transplantation for Patients with Multiple Myeloma Who Relapsed after Autografting. a Study from the Cmwp of EBMT ",
    "article_date": "December 7, 2017",
    "session_type": "732. Clinical Allogeneic Transplantation: Results: Poster I",
    "abstract_text": "Introduction Haploidentical stem cells are becoming an alternative stem cell source for patients lacking an HLA-identical sibling or 10/10 HLA-matched donor. While an increasing number of studies for patients with acute leukemia, malignant lymphoma, and MDS are reported there are only very few results of haploidentical stem cell transplants in myeloma patients. Method and patients In EBMT registry 50 MMpatients with a median age of 55 y (r: 37 - 73) with relapse after autograft who received a mismatched related stem cell graft after myeloablative (n = 12, 25%) or reduced intensity conditioning (n = 37, 75%) between 2004 and 2014 were reported. The median time to relapse after single (n = 28, 56%) or tandem (n = 18, 36%) autologous stem cell transplantation was 6.2 months (r: 0.1 - 30.5) and the median time between last autograft and allograft was 17.4 months (r: 2 = 74 months). At time of allograft 4 (8%) of the patients were in CR, 21 (42%) in PR, 9 (18%) had stable disease or minor response, and 15 (30%) had progressive disease. The majority (84%) received peripheral blood stem cells as graft source and GvHD prophylaxis with ex- or in-vivo T-cell depletion (CD34 selection or ATG) (Cyclophosphamide post transplant) was performed in 37% of the patients while 63% did not receive any in-vivo or ex-vivo T-cell depletion. Results After a median follow-up of 52 months (95% CI: 12-112) the cumulative incidence of non-relapse mortality at 1 year was 20% (95% CI: 9 - 31%) and the cumulative incidence of relapse at 3 years was 56% (95% CI: 42 - 70%) resulting in an estimated 3-year PFS and OS of 15% (95% CI: 5 - 26%) 31% (95% CI: 7 - 45%), respectively. Significant factor for improved OS in a univariate analysis was only the use of BM (3 y OS: 71% (95% CI: 38 -100%) vs. 24% (95% CI: 11 - 38%), p = 0.02) and for relapse a higher but not significant incidence for ex-vivo T-cell depletion was observed (p = 0.07). The use of cyclophosphamide post transplantation as GvHD prophylaxis did not influence NRM, relapse incidence, PFS, OS, or chronic GvHD. Conclusion Haploidentical stem cell transplantation after relapse to an autograft is feasible for MMpatients. Major treatment failure is the high incidence of relapse. Post-transplant cyclophosphamide had no major impact on outcome in this limited number of patients. Disclosures Dreger: medac: Other: Travel grants; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Riemser: Consultancy, Research Funding; Jansen: Consultancy; Jansen: Consultancy; medac: Other; medac: Other: Travel grants; medac: Other: Travel grants; medac: Other; Gilead: Consultancy, Speakers Bureau; medac: Other; medac: Other; Riemser: Consultancy, Research Funding; Riemser: Consultancy, Research Funding; Riemser: Consultancy, Research Funding; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Jansen: Consultancy; Jansen: Consultancy; Jansen: Consultancy; Gilead: Consultancy, Speakers Bureau; Riemser: Consultancy, Research Funding; Riemser: Consultancy, Research Funding; Gilead: Consultancy, Speakers Bureau; Riemser: Consultancy, Research Funding; Riemser: Consultancy, Research Funding; Riemser: Consultancy, Research Funding; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Riemser: Consultancy, Research Funding; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Riemser: Consultancy, Research Funding; Jansen: Consultancy; Riemser: Consultancy, Research Funding; Jansen: Consultancy; Gilead: Consultancy, Speakers Bureau; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Jansen: Consultancy; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Jansen: Consultancy; Gilead: Consultancy, Speakers Bureau; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Jansen: Consultancy; Gilead: Consultancy, Speakers Bureau; Jansen: Consultancy; Gilead: Consultancy, Speakers Bureau; medac: Other: Travel grants; Jansen: Consultancy; Gilead: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; medac: Other: Travel grants; medac: Other: Travel grants; AbbVie: Consultancy, Other: Travel grants, Speakers Bureau. Corradini: Amgen: Honoraria; Novartis: Honoraria; Roche: Honoraria; Sanofi: Honoraria; Takeda: Honoraria; Celgene: Honoraria; Janssen: Honoraria; Gilead: Honoraria. Zuckerman: BioSight Ltd.: Consultancy. Ciceri: GSK: Other: B-thalassemia gene therapy was developed by Fondazione Telethon and Ospedale San Raffaele and has been inlicenced by GSK that provides funding for the clinical trial, Research Funding. Petersen: Sanofi: Membership on an entity's Board of Directors or advisory committees. Sch\u00f6nland: Sanofi: Research Funding; prothena: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Speakers Bureau. Garderet: Amgen: Honoraria; Takeda: Honoraria.",
    "topics": [
        "hematopoietic stem cell transplantation",
        "multiple myeloma",
        "cyclophosphamide",
        "transplantation",
        "transplantation, autologous",
        "allografting",
        "graft-versus-host disease",
        "human leukocyte antigens",
        "tissue transplants",
        "autologous stem cell transplant"
    ],
    "author_names": [
        "Nicolaus Kroeger",
        "Diderik-Jan Eikema",
        "Nina Simone Knelange",
        "Yener Koc",
        "Jose M Moraleda",
        "Peter Dreger, MD",
        "Harry C. Schouten, MD",
        "Lothar Kanz",
        "Johanna Tischer, MD",
        "Paolo Corradini, MD",
        "Hendrik Veelken, MD PhD",
        "Michel Schaap, MD PhD",
        "Tsila Zuckerman, MD",
        "Liisa Volin",
        "Nigel H. Russell",
        "Pavel Jindra, MD PhD",
        "Yves Beguin, MD PhD",
        "Gerhard Ehninger",
        "Fabio Ciceri, MD",
        "Didier Blaise",
        "Jose L. Diez-Martin, MD PhD",
        "Eefke Petersen, MD",
        "Stefan Sch\u00f6nland, MD",
        "Laurent Garderet, MD PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Nicolaus Kroeger",
            "author_affiliations": [
                "Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Diderik-Jan Eikema",
            "author_affiliations": [
                "EBMT Data Office, Leiden, Netherlands "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nina Simone Knelange",
            "author_affiliations": [
                "EBMT Data Office, Leiden, Netherlands "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yener Koc",
            "author_affiliations": [
                "Medical Park Hospitals, Stem Cell Transplant Unit, Antalya, TUR "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose M Moraleda",
            "author_affiliations": [
                "Hospital Virgen de la Arrixaca, El Palmar, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Peter Dreger, MD",
            "author_affiliations": [
                "Department of Internal Medicine V, Universit\u00e4tsklinikum, Heidelberg, Germany "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Harry C. Schouten, MD",
            "author_affiliations": [
                "Department of Hematology, Academische Ziekenhuis, Maastricht, Netherlands "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lothar Kanz",
            "author_affiliations": [
                "University Hospital, Tuebingen, Germany "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Johanna Tischer, MD",
            "author_affiliations": [
                "Deparment of Medicine III, University Hospital, LMU Munich, Munich, Germany "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paolo Corradini, MD",
            "author_affiliations": [
                "University of Milan, Milan, Italy "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Hendrik Veelken, MD PhD",
            "author_affiliations": [
                "Department of Hematology, Leiden University Medical Center, Leiden, Netherlands "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michel Schaap, MD PhD",
            "author_affiliations": [
                "Radboud University Medical Centre, Nijmegen, Netherlands "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tsila Zuckerman, MD",
            "author_affiliations": [
                "Rambam Medical Center, Haifa, Israel "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Liisa Volin",
            "author_affiliations": [
                "Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, FIN "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nigel H. Russell",
            "author_affiliations": [
                "Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pavel Jindra, MD PhD",
            "author_affiliations": [
                "Charles University Hospital, Plzen, CZE "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yves Beguin, MD PhD",
            "author_affiliations": [
                "Department of Hematology, University of Liege, Liege, Belgium "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gerhard Ehninger",
            "author_affiliations": [
                "Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabio Ciceri, MD",
            "author_affiliations": [
                "San Raffaele Scientific Institute, Milan, Italy "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Didier Blaise",
            "author_affiliations": [
                "Institut Paoli Calmettes, Department of Hematology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Marseille, France "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose L. Diez-Martin, MD PhD",
            "author_affiliations": [
                "Hospital Gregorio Maran\u00f3n, Madrid, ESP "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eefke Petersen, MD",
            "author_affiliations": [
                "University Medical Centre Utrecht, Utrecht, Netherlands "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefan Sch\u00f6nland, MD",
            "author_affiliations": [
                "Amyloidosis Center, University Hospital, Heidelberg, Germany "
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Laurent Garderet, MD PhD",
            "author_affiliations": [
                "Service d'H\u00e9matologie et Th\u00e9rapie Cellulaire, Hopital Saint Antoine, Paris, France"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-09T06:47:02",
    "is_scraped": "1"
}